Novartis stock follows Goldman Sachs cut to CHF 110.00 target

Novartis stock was trading at EUR 128.34 at Lang & Schwarz on September 29, 2026 at 2:39 p.m. CEST, down 0.69 percent versus the prior close of EUR 129.23. The central valuation signal is a lower Goldman Sachs target of CHF 110.00.

Goldman Sachs lowers target

According to finanzen.ch on September 22, 2026, Goldman Sachs cut its Novartis price target from CHF 113.00 to CHF 110.00 and kept a Sell rating.

Analyst James Quigley said the valuation reflected more of the risks, while still seeing correction risk relative to the broader pharmaceutical industry. The target change gives investors a concrete counterweight to the company's earnings delivery.

Revenue reaches USD 14.95 billion

MarketBeat reported that Novartis generated USD 14.95 billion in revenue and USD 2.41 earnings per share for the quarter reported on June 30, 2026. The same report cited a return on equity of 38.56 percent and a net margin of 23.29 percent.

Investing.com lists the latest release date as July 21, 2026, with earnings per share of USD 2.41 against a USD 2.17 forecast, a USD 0.24 beat. That comparison puts the Goldman Sachs downgrade beside a measurable earnings outperformance.

Next earnings date is October 27

Investing.com lists October 27, 2026 as Novartis' next earnings date. The company investor calendar also listed a Santander Virtual Pharma Day for September 29, 2026, according to Novartis.

For investors, the next report will test whether the recent quarterly earnings comparison can offset the more cautious valuation view from Goldman Sachs.

Novartis stock trades below prior close

At Lang & Schwarz, Novartis was trading at EUR 128.34 on September 29, 2026 at 2:39 p.m. CEST, down 0.69 percent against the EUR 129.23 prior close. The reference price is an intraday euro quotation.

More news and analysis on Novartis stock